Rise and Shine: What you need to know before the ASX opens
Coming up on Stockhead today, what you need to know about the state of renewables in Australia right now, why the International Space Station is getting lithium-ion batteries, and how all the dots point to commodity prices rising.
But first, here’s what you need to know right now:
Not much data today: just the ANZ Roy Morgan weekly consumer confidence figures.
Just one company has shares coming out of escrow today: Lepidico (ASX:LPD), with 3.6 million. You can view our recent wrap of companies releasing escrowed shares here.
The following six companies may appear from a trading halt today:
Gold: $USD1320.02 ($1,857.80) +0.65%
Silver: $USD15.56 +0.76%
Oil (Brent): $USD67.20 +0.36%
Oil (WTI): $USD59.02 -0.12%
Coal: $USD88.22 -0.63%
Iron ore 62% fe: $USD85.89 +0.28%
Want this headstart in your inbox every morning at 8am? Go on. Subscribe here. It’s free
These were the five most-discussed stocks on trading gossip forum HotCopper at close on Monday:
— HotCopper (@HotCopper) March 25, 2019
Emerge Gaming (ASX:EM1) was still generating plenty of discussion thanks to its tie-up with iCandy (ASX:ICI), while Nuheara (ASX:NUH) revealed that the UK’s NHS has reclassified its IQBuds Boost as “niche technology” hearables.
They’ll no longer be considered hearing aids, a category Nuheara has been targeting for some time.
Alaska-focused Zinc miner White Rock Minerals (ASX:WRM) got a boost yesterday, following news that the $1.1 billion Sandfire Resources (ASX:SFR) could inject up to $30 million in the company, in return for a 70 per cent stake.
Shares in the minnow jumped 27 per cent to 0.7 cents.
ApplyDirect (ASX:AD1) rose 46 per cent to 2c on Monday after announcing late on Friday that it had completed an acquisition of a software company, as well as raising $990,000 from a placement to an institutional investors.
As much as $90 million was wiped from the market cap of OncoSil Medical (ASX:OSL) as it slumped by 87 per cent after getting some bad news from UK medical authorities.
The biotech aims to treat liver and pancreatic cancer by implanting a tiny device directly into tumours with a needle to irradiate them.
However, the British Standards Institute concluded that “insufficient clinical benefit has been demonstrated to recommend approval” for Oncosil’s treatment.
That’s all you need to know. Go go go!